10/09/2026 · Blog

TB-500 Research: Why Full-Length Thymosin β4 Evidence Cannot Be Assigned to a Seven-Amino-Acid Fragment

TB-500 Thymosin β4 Fragment specification sheet

What Is TB-500?

TB-500 is a synthetic N-terminally acetylated heptapeptide with the sequence:

Ac-LKKTETQ

It corresponds to amino-acid residues 17–23 of human thymosin β4 (Tβ4).

SUNONE supplies research-grade TB-500 for qualified laboratory, analytical and manufacturing research.

SUNONE TB-500 Product Page:

TB-500 Is Not Full-Length Thymosin β4

This is one of the most important distinctions in TB-500 research.

Full-length thymosin β4 contains 43 amino acids.

TB-500 contains only a short seven-amino-acid region derived from that sequence.

The two materials are therefore not molecularly identical.

This matters because a biological effect observed with full-length thymosin β4 cannot automatically be assigned to TB-500.

A more accurate evidence framework is:

full-length Tβ4 evidence ≠ TB-500 fragment evidence.

Why Is the LKKTETQ Region Important?

The LKKTETQ region lies within an important actin-associated domain of thymosin β4.

Research involving this region has explored:

  • actin-related biology;
  • cell migration;
  • cytoskeletal regulation;
  • wound-healing models;
  • angiogenesis-related pathways;
  • fibrotic signaling.

Older mechanistic studies show that residues around the 17–23 region contribute to thymosin β4 interaction with actin.

However, full-length Tβ4 contains additional structural and functional regions.

That means the fragment may reproduce some local sequence-associated biology without reproducing every property of the intact molecule.

What Does the 2026 Evidence Review Show?

A 2026 scoping review examined the literature on thymosin β4 and TB-500 in tissue healing and musculoskeletal research.

The review included 80 studies.

Its most important finding for researchers was not simply that repair-related pathways were reported.

It was that:

most studies evaluated full-length thymosin β4 rather than TB-500.

Direct TB-500 evidence was extremely limited.

Human evidence was also concentrated mainly in ocular, corneal, skin and soft-tissue research, while direct human evidence relevant to tendon, ligament, muscle and other musculoskeletal applications remained sparse.

This is important because online TB-500 marketing often presents the larger thymosin β4 literature as though it were direct TB-500 evidence.

Scientifically, that is not the same thing.

Scientists conducting peptide research in a laboratory
Scientists working with laboratory equipment during peptide research.

Why Analytical Identity Matters

TB-500 has been analytically identified as the N-acetylated thymosin β4 17–23 fragment, Ac-LKKTETQ.

For laboratory research, researchers should therefore verify:

  • correct seven-amino-acid sequence;
  • N-terminal acetylation;
  • molecular mass;
  • HPLC purity;
  • peptide-related impurities;
  • salt or chemical form;
  • batch consistency.

A label that simply says “Thymosin Beta-4” is not sufficient to prove that the material is TB-500.

Likewise, a TB-500 fragment should not automatically be treated as full-length thymosin β4.

What Do Current TB-500 Reviews Say?

Current online TB-500 reviews are mixed.

Positive anecdotal reports sometimes mention:

  • improved perceived recovery;
  • reduced joint discomfort;
  • reduced inflammation;
  • improved mobility;
  • faster return to normal activity.

Negative reports include:

  • fatigue;
  • brain fog;
  • emotional numbness;
  • headache;
  • dizziness;
  • feeling generally unwell;
  • no noticeable benefit.

Many posts involve TB-500 combined with BPC-157 or other compounds, making attribution especially difficult.

Product identity and analytical quality are also usually unknown.

Therefore:

TB-500 reviews are anecdotal search sentiment—not controlled clinical evidence.

They should not be interpreted as reviews of SUNONE Research Grade TB-500.

What Does FDA Say About TB-500?

FDA has stated that it has not identified human exposure data for drug products containing the thymosin β4 fragment known as TB-500.

The agency has also highlighted potential concerns involving:

  • peptide aggregation;
  • peptide-related impurities;
  • API characterization;
  • immunogenicity.

This reinforces an important research principle:

preclinical biological plausibility is not the same as established human safety or efficacy.

What Should Researchers Check When Choosing a TB-500 Supplier?

SUNONE currently lists:

Product: TB-500
Sequence: Ac-LKKTETQ
Synonyms: TB500, N-acetyl-LKKTETQ, Thymosin β4 Fragment 17–23
CAS: 885340-08-9
Formula: C38H68N10O14
Molecular Weight: 889.0 g/mol
Purity: ≥99.1% HPLC
Form: Lyophilized Peptide
Grade: Research / HPLC
Storage: -20°C

Final identity, purity, chemical form, storage conditions and analytical results should always be verified using the applicable batch-specific COA, HPLC, MS and SDS documentation.

Final Thoughts

A common search asks:

“What does TB-500 do?”

For researchers, a more important question is:

“Was the published experiment actually performed with TB-500, or with full-length thymosin β4?”

That distinction creates a stronger scientific framework:

sequence identity → fragment vs full-length molecule → actin-associated biology → preclinical evidence → human evidence gap → analytical verification.

For laboratories comparing a TB-500 supplier, correct Ac-LKKTETQ identity and batch-specific analytical documentation should take priority over broad “healing peptide” claims.


Leave a Reply

Your email address will not be published. Required fields are marked *

للاستخدام البحثي والتصنيعي فقط. تُورَّد المنتجات إلى الشركات المؤهَّلة وفقًا لقوانين وأنظمة بلد الوجهة. غير مخصّصة للاستخدام الشخصي أو التشخيصي أو العلاجي ما لم تكن مسجَّلة ومرخَّصة حسب الأصول.